Copyright
©The Author(s) 2020.
World J Gastroenterol. Oct 14, 2020; 26(38): 5896-5910
Published online Oct 14, 2020. doi: 10.3748/wjg.v26.i38.5896
Published online Oct 14, 2020. doi: 10.3748/wjg.v26.i38.5896
Ref. | Year | Country | Patients | Female | Mean age | Design | Biochemical remission (%) | Follow-up | Mean dose2 |
Tacrolimus | |||||||||
Zolfino et al[29] | 2002 | United Kingdom | 5 | 3/5 | 28.4 ± 12.26 | Retrospective | 2/5 (40) | NR | 2-4 |
Aqel et al[30] | 2004 | United States | 11 | 10/11 | 63 | Retrospective | 10/11 (91) | 161 | 3.0 |
Chatur et al[31] | 2005 | Canada | 3 | NR | NR | Retrospective | 0/3 (0) | 26.5 (10–54) | 2-4 |
Larsen et al[32] | 2007 | Denmark | 9 | 8/9 | 36 ± 16.06 | Retrospective | 9/9 (100) | 21.25 ± 8.37 | 2 (2-4) |
Yeoman et al[33] | 2011 | United Kingdom | 9 | 5/9 | 39.5 ± 18.07 | Retrospective | 7/9 (77.8) | NR | NR |
Tannous et al[34] | 2011 | United States | 13 | 10/13 | 40.6 ± 12.5 | Retrospective | 12/13 (92.3) | 1-65 | 2-6 |
Than et al[35] | 2016 | German, United Kingdom | 17 | 11/17 | 34.5 ± 15.03 | Retrospective | 9/17 (53) | 84 ± 53.45 | 2 (0.5-5)1 |
Efe et al[36] | 2017 | Europe, United States, Canada, and China | 80 | 60/80 | 34.7 ± 11.78 | Retrospective | 58/80 (72.5) | 85.75 ± 37.83 | 3 (0-6)1 |
Pape et al[17] | 2020 | Belgium, Netherlands | 10 | 8/10 | 38 ± 13.67 | Retrospective | 5/10 (50) | 14.5 ± 6.47 | 3.5 ± 1.72 |
MMF | |||||||||
Richardson et al[37] | 2000 | United Kingdom | 7 | 6/7 | 27.28 ± 10.45 | Retrospective | 5/7 (71.4) | 43 ± 13.92 | 2 |
Zolfino et al[29] | 2002 | United Kingdom | 2 | 1/2 | 17.5 ± 2.12 | Retrospective | 0/2 (0) | NR | 2 |
Devlin et al[38] | 2004 | Canada | 5 | 4/5 | 54 ± 2.10.83 | Retrospective | 5/5 (100) | NR | 1-2 |
Chatur et al[31] | 2005 | Canada | 11 | NR | NR | Retrospective | 7/11 (63.6) | 26.5 (10–54) | 0.5-2 |
Czaja et al[39] | 2005 | United States | 7 | NR | NR | Retrospective | 0/7 (0) | 19 ± 7 | 0.5-3 |
Inductivo-Yu et al[40] | 2007 | United States | 15 | 11/15 | 60 ± 15 | Retrospective | 11/15 (73.3) | 41 | 2 |
Hlivko et al[41] | 2008 | United States | 12 | NR | NR | Retrospective | 8/12 (66.7) | NR | 0.5-2 |
Hennes et al[42] | 2008 | Germany | 36 | 28/36 | 41.5 ± 13.24 | Retrospective | 14/36 (39) | 35.38 ± 21.4 | 1.75 (0.5-3)1 |
Wolf et al[43] | 2009 | United States | 16 | NR | NR | Retrospective | 12/16 (75) | NR | 1-2 |
Sharzehi et al[44] | 2010 | United States | 17 | 13/17 | 50 | Retrospective | 8/17 (48) | 12 | 0.5-2 |
Yeoman et al[33] | 2011 | United Kingdom | 2 | 1/2 | 31.5 ± 19.51 | Retrospective | 1/2 (50) | NR | NR |
Baven-Pronk et al[45] | 2011 | The Netherlands | 30 | 24/30 | NR | Retrospective | 14/30 (46.7) | 39.5 ± 22.51 | 0.5-3 |
Jothimani et al[46] | 2014 | India, United Kingdom | 19 | 16/19 | 52.25 ± 16.52 | Retrospective | 14 /19 (73.6) | 45.4 ± 21.13 | 1-2 |
Roberts et al[47] | 2018 | Australia | 105 | 92/105 | 52.5 ± 3.65 | Retrospective | 63/105 (60) | 38.75 ± 10.14 | 2.0 (1.0-2.0)1 |
Efe et al[36] | 2017 | Europe, United States, Canada, and China | 121 | 96/121 | 41.25 ± 13.45 | Retrospective | 84/121 (69.4) | 66.25 ± 31.77 | 1 (0-2)1 |
Giannakopoulos et al[18] | 2019 | Sweden | 22 | 12/22 | 50 ± 12.57 | Retrospective | 10/22 (45.5) | 71 (10-54)1 | 2.0 (1.0–2.5)1 |
Outcomes | Certainty assessment | Patient | Certainty | Importance | ||||||
Studies (n) | Study design | Inconsis-tency | Indirect-ness | Imprecision | Other considerations | Per event/in total (%) | ||||
Tacrolimus | ||||||||||
Biochemical remission | 9 | Observational | Serious1 | Serious2 | Not serious | Not serious | None | 112/157 (71.3) | +OOO Very low | Critical |
Adverse events | 7 | Observational | Serious1 | Serious2 | Not serious | Not serious | None | 28/143 (19.6) | +OOO Very low | Important |
Mortality | 9 | Observational | Serious1 | Not serious | Not serious | Not serious | None | 14/157 (8.9) | +OOO Very low | Critical |
MMF | ||||||||||
Biochemical remission | 16 | Observational | Serious1 | Serious2 | Not serious | Not serious | Dose response gradient | 256/427 (59.9) | +OOO Very low | Critical |
Adverse events | 13 | Observational | Serious1 | Serious2 | Not serious | Not serious | None | 97/416 (23.3) | +OOO Very low | Important |
Mortality | 16 | Observational | Serious1 | Not serious | Not serious | Not serious | Publication bias strongly suspected | 22/427 (5.2) | +OOO Very low | Critical |
- Citation: Abdollahi M, Khalilian Ekrami N, Ghojazadeh M, Boezen HM, Somi M, Alizadeh BZ. Tacrolimus and mycophenolate mofetil as second-line treatment in autoimmune hepatitis: Is the evidence of sufficient quality to develop recommendations? World J Gastroenterol 2020; 26(38): 5896-5910
- URL: https://www.wjgnet.com/1007-9327/full/v26/i38/5896.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i38.5896